Participated · Equity · Apr 2026

Founded in 2021 and based in Shanghai, StairMed develops minimally invasive implantable brain-machine interfaces and neuromodulation systems, including ultra-flexible microelectrodes and wireless BMI implants. The company has advanced proprietary electrodes, systems, algorithms, and surgical robotics, and completed China’s first prospective clinical trial for an invasive BMI in 2025. In early 2026 StairMed implanted a 256-channel wireless high-throughput invasive BMI system (WRS02) using its surgical robot and validated brain-controlled interaction functions. Its BMI product has received access to the NMPA Green Channel for Innovative Medical Devices. StairMed plans large-scale, multi-center registration trials beginning mid-2026 aiming to enroll ~40 patients that year and expects cumulative implants to reach several dozen by end-2026. In parallel, it has developed a closed-loop ultra-low-damage deep brain stimulation system that has been implanted in four patients in clinical research, with formal clinical trials targeted for 2027. The company’s stated long-term mission is to integrate brain and machine intelligence.

Led · Series C · Jul 2021

dMed-Clinipace is a merged global full-service CRO formed by the combination of dMed Global and Clinipace Incorporated. The company provides clinical development, regulatory, pharmacovigilance and clinical analytics services with therapeutic focus in oncology, rare disease, gastroenterology, nephrology and women’s health. Led by Global Chairman and CEO Dr. Lingshi Tan, the CRO supports end-to-end clinical programs. The Series C+ financing proceeds helped finance the merger announced in April 2021. The organization employs more than 1,700 staff across 22 offices in the Americas, Europe and Asia-Pacific, including over 700 staff in China. Investors from prior angel, A and B rounds have continued to increase their contributions since dMed’s inception in 2016. dMed is a full-service clinical CRO that provides consulting, regulatory affairs and strategy, early clinical development, clinical science and medical affairs, clinical operations, biostatistics and programming, data management, drug safety and pharmacovigilance, quality assurance and information solutions. The company leverages and integrates China’s new regulatory framework to offer innovative drug development strategies and help clients expand globally into the world’s second-largest pharmaceutical market. dMed says its collaboration models aim to raise efficiency in clinical R&D, shorten research cycles, and boost success rates for innovative pharma companies. It has established offices in major cities including Shanghai, Beijing, Wuhan, New York, Washington, San Francisco, and Brussels. The company is led by Founder, Chairman and CEO Dr. Lingshi Tan and employs around 600 professionals globally. The business targets both Chinese and international pharmaceutical and medical device clients seeking to run clinical programs in China and worldwide. dMed is a global “next generation” full-service clinical CRO providing end-to-end industry solutions for pharmaceutical and medical device companies. Its offerings span consulting, early development and clinical pharmacology, clinical operations, biostatistics and programming, data management, safety and pharmacovigilance, clinical science, quality assurance, and regulatory affairs and strategy. The company has offices in major cities including Shanghai, Beijing, Wuhan, New York, Washington, San Francisco, and Brussels, and employs more than 600 professionals globally. dMed completed the acquisition of Target Health, a New York-based CRO, mid-year to extend its global footprint and add technologies to its services. The company plans to use the new funding to accelerate expansion of its clinical operations and information technology infrastructure, and to extend global capacity in clinical development and product registration. Led by founder and CEO Dr. Lingshi Tan, dMed has attracted industry elites and experts in China and the US since its launch three years ago. dMed is a China-based contract research organization that provides comprehensive services to biopharmaceutical and medical device companies in China and globally. Its offerings include advising customers on clinical development plans, regulatory strategy, approval processes, and full clinical trial support. The company was founded in 2016 by Lingshi Tan. dMed raised $8M in a Series A round to support growth. It intends to use the funds to expand its assurance and clinical operations teams. Founder Lingshi Tan previously served as Pfizer’s Vice President of Worldwide Development Operations and Chairman and General Manager of Pfizer (China) R&D.

Led · Series C · Jul 2021

dMed-Clinipace is a global full-service CRO offering clinical development, regulatory, pharmacovigilance and clinical analytics services. The company has therapeutic expertise in oncology and rare disease, with additional focus in gastroenterology, nephrology and women's health. It was formed through the April 2021 merger of Shanghai-based dMed Global and Morrisville, North Carolina–headquartered Clinipace. The combined entity has more than 1,700 staff across 22 offices in the Americas, Europe and Asia‑Pacific, including over 700 staff in China. dMed-Clinipace completed a US$50 million Series C+ financing to help finance the merger and to accelerate global growth and expand its investor base. Management said new investors will bring resources and strategic insight to support the company’s global expansion. Founded in 2003 as a software company, Clinipace has grown into a global, full-service contract research organization. The company provides services in clinical development, regulatory affairs, and clinical analysis. Its geographic coverage includes North America, Latin America, Asia-Pacific, and Eastern and Western Europe. Clinipace says it aims to bring new therapies and medications to market, impact patients’ lives, and offer partnership and efficiency beyond traditional clinical research organizations. CEO Jason Montelone joined the company in 2017 after co-founder Jeff Williams resigned and brings more than 20 years of health care and life-science industry experience. Financially, the company has continued to raise private capital, most recently selling $4 million of private equity per an SEC filing, following prior raises of $5.7 million in September 2018 and $10 million in December 2017. Clinipace Worldwide is a clinical research organization that provides clinical development and regulatory services to pharmaceutical, biotechnology, and medical device companies. The firm helps execute regulatory strategies, optimize clinical development timelines and complete high-quality trials across therapeutic areas including oncology, nephrology, urology, gastroenterology, nutrition, cardiology, diabetes, immunology, infectious diseases and orthopedics. The company raised $3 million in a private stock offering, according to an SEC filing. Clinipace filed a Form D with the Securities and Exchange Commission on Nov. 17 and declined to disclose how it intends to use the proceeds. The company is led by CEO Jason Monteleone, who joined in October 2017 after serving as a strategic consultant and has over 20 years of experience in healthcare and life sciences. Monteleone holds an MBA in finance from Temple University's Fox School of Business and a BS in business administration from Millersville University of Pennsylvania. Clinipace Worldwide is a technology‑amplified dCRO that delivers clinical operations, regulatory and strategic development services powered by its proprietary TEMPO eClinical platform. The company supports therapeutic areas including cardiovascular, CNS, oncology, infectious disease and others and has built a global footprint through five acquisitions in as many years. Clinipace reported a three‑year growth rate of 348% and added over 450 jobs from 2012 to 2014. It now employs about 700 global staff and has managed over 1,500 clinical research studies, activated more than 23,000 sites, enrolled over 330,000 subjects and handled over 300 regulatory and strategic engagements. The company intends to use new capital to continue building therapeutic expertise, expand capacity to deliver services, and to fund a pipeline of corporate acquisitions. Clinipace’s global headquarters are in Research Triangle Park, NC, with additional domestic and international offices. Clinipace Worldwide provides clinical research services to pharmaceutical, biotechnology and medical device companies, with a niche in oncology and a growth-by-acquisition strategy. The company recently acquired Paragon Biomedical, adding offices in Irvine, California; High Wycombe, England; and Trivandrum, India. Clinipace reported more than 430 staff, contractors and consultants after the Paragon deal and moved up on Inc.’s list of fastest-growing private companies to No. 260. Management says the sales pipeline is rich and anticipates robust hiring to support new clients and projects. Open roles listed on the company website include clinical data managers, data specialists and therapeutic-specific clinical research associates. The company uses acquisitions to expand therapeutic expertise, site management capabilities and clinical operations.